Cinclus Pharma
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in … Read more
Cinclus Pharma (CINPHA) - Net Assets
Latest net assets as of : Skr- SEK
Based on the latest financial reports, Cinclus Pharma (CINPHA) has net assets worth Skr- SEK as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr-) and total liabilities (Skr-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Cinclus Pharma - Net Assets Trend (None–None)
This chart illustrates how Cinclus Pharma's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cinclus Pharma (None–None)
The table below shows the annual net assets of Cinclus Pharma from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to Cinclus Pharma's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
Cinclus Pharma Competitors by Market Cap
The table below lists competitors of Cinclus Pharma ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SysJust Co., Ltd.
TWO:3158
|
$48.37 Million |
|
ImageneBio, Inc.
NASDAQ:IMA
|
$48.40 Million |
|
Magni Tech Industries Bhd
KLSE:7087
|
$48.40 Million |
|
Zeotech Ltd
AU:ZEO
|
$48.41 Million |
|
Thai Nguyen International Hospital JSC
VN:TNH
|
$48.35 Million |
|
6934
TWO:6934
|
$48.34 Million |
|
Wir Asia Tbk PT
JK:WIRG
|
$48.34 Million |
|
Cinclus Pharma Holding AB (publ)
F:J8P
|
$48.34 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cinclus Pharma's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares Cinclus Pharma's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Cinclus Pharma utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares Cinclus Pharma's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $94,923,042
- Average return on equity (ROE) among peers: -56.73%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cinclus Pharma (CINPHA) | Skr- | N/A | N/A | $48.37 Million |
| BioGaia AB (publ) (BIOG-B) | $230.35 Million | 33.15% | 0.21x | $714.80 Million |
| Dicot AB (DICOT) | $73.40 Million | -109.26% | 0.16x | $55.17 Million |
| Enzymatica publ AB (ENZY) | $76.61 Million | -64.91% | 0.64x | $21.33 Million |
| Enorama Pharma AB (ERMA) | $17.02 Million | -96.01% | 1.28x | $549.55K |
| Gabather AB (publ) (GABA) | $10.96 Million | -155.04% | 0.40x | $732.74K |
| Klaria Pharma Holding AB (KLAR) | $-452.69K | 0.00% | 0.00x | $14.51 Million |
| Moberg Pharma AB (publ) (MOB) | $76.79 Million | -8.31% | 0.20x | $38.42 Million |
| Nanexa AB (NANEXA) | $101.53 Million | -11.22% | 0.36x | $39.34 Million |
| Newbury Pharmaceuticals AB (NEWBRY) | $51.92 Million | -29.67% | 0.75x | $570.29K |
| Orexo AB (ORX) | $311.10 Million | -126.01% | 0.76x | $45.01 Million |